AdhesionScore

Colorectal cancer (CRC) is the third most prevalent malignancy globally, with approximately 1.9 million new cases annually. Although surgical resection remains the primary treatment, up to 30% of patients experience recurrence, and no predictive test in the immediate postoperative period is currently available. AdhesionScore addresses this gap through a cell-based in vitro assay using pre- and postoperative blood samples to assess surgical response and predict recurrence risk within 48 hours, guiding improved clinical decision-making.